Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature için istatistikler
Toplam ziyaret
views | |
---|---|
Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature | 0 |
Aylık toplam ziyaret
views | |
---|---|
Mayıs 2024 | 0 |
Haziran 2024 | 0 |
Temmuz 2024 | 0 |
Ağustos 2024 | 0 |
Eylül 2024 | 0 |
Ekim 2024 | 0 |
Kasım 2024 | 0 |